To the Editor Jung et al1 conducted an important study to investigate whether intermittent pneumatic compression (IPC) was noninferior to IPC+low-molecular-weight (LMW) heparin for preventing venous thromboembolism (VTE). The primary end point was occurrence of VTE. The observed VTE rates were 3.5% and 0.6% for IPC and IPC+LMW heparin, respectively. The upper 95% CI for the rate difference was 5.1%, beyond the prespecified margin of 2%. Therefore, for efficacy, we cannot claim IPC is noninferior to IPC+LMW heparin. However, for bleeding episodes, the corresponding rates were 1.2% and 9.1% for IPC and IPC+LMW heparin, respectively. Because LMW heparin had higher bleeding risk, Jung et al1 recommended further studies to identify patients with high VTE risk.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
McCaw ZR, Piantadosi S, Wei L. Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective. JAMA Surg. 2019;154(3):270–271. doi:10.1001/jamasurg.2018.4294
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: